PRISMA-DTA Checklist

Section/topic	#	PRISMA-DTA Checklist Item	Reported on Page Number/Line Number	Reported on Section/Paragraph
TITLE/ABSTRACT				
Title	1	Identify the report as a systematic review (+/- meta-analysis) of diagnostic test accuracy (DTA) studies.	Page 1/Line 1-3	Title
Abstract	2	Abstract: See PRISMA-DTA for abstracts (Table 2).	Page 2-3/Line32-60	Abstract
INTRODUCTION				
Rationale	3	Describe the rationale for the review in the context of what is already known.	Page3-4/Line67-92	Introduction/Para1-3
Clinical role of index test	D1	State the scientific and clinical background, including the intended use and clinical role of the index test, and if applicable, the rationale for minimally acceptable test accuracy (or minimum difference in accuracy for comparative design).	Page3-4/Line67-92	Introduction/Para1-3
Objectives	4	Provide an explicit statement of question(s) being addressed in terms of participants, index test(s), and target condition(s).	Page4/Line92-97	Introduction/Para3
METHODS				
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	Page5/Line104	METHODS/Para1
Eligibility criteria	6	Specify study characteristics (participants, setting, index test(s), reference standard(s), target condition(s), and study design) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	Page5-6/Line106-129	METHODS/Para2-4
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	Page5/Line107	METHODS/Para1
Search	8	Present full search strategies for all electronic databases and other sources searched, including any limits used, such that they could be repeated.	Page5/Line108-109	METHODS/Para2
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	Page5-6/Line106-129	METHODS/Para2-4
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	Page5-6/Line106-129	METHODS/Para2-4
Definitions for data extraction	11	Provide definitions used in data extraction and classifications of target condition(s), index test(s), reference standard(s) and other characteristics (e.g. study design, clinical setting).	Page5-6/Line106-129	METHODS/Para2-4

Risk of bias and applicability	12	Describe methods used for assessing risk of bias in individual studies and concerns regarding the applicability to the review question.	Page6/Line131-134	METHODS/Para5
Diagnostic accuracy measures	13	State the principal diagnostic accuracy measure(s) reported (e.g. sensitivity, specificity) and state the unit of assessment (e.g. per-patient, per-lesion).	Page6/Line131-134	METHODS/Para5
Synthesis of results	14	Describe methods of handling data, combining results of studies and describing variability between studies. This could include, but is not limited to: a) handling of multiple definitions of target condition. b) handling of multiple thresholds of test positivity, c) handling multiple index test readers, d) handling of indeterminate test results, e) grouping and comparing tests, f) handling of different reference standards	Page6/Line131-134	METHODS/Para5
Meta-analysis	D2	Report the statistical methods used for meta-analyses, if performed.	Page6/Line137-145	METHODS/Para6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	Page6/Line137-145	METHODS/Para6
RESULTS				
Study selection	17	Provide numbers of studies screened, assessed for eligibility, included in the review (and included in meta-analysis, if applicable) with reasons for exclusions at each stage, ideally with a flow diagram.	Page6-7/Line148-164	RESULTS/Para1-2
Study characteristics	18	For each included study provide citations and present key characteristics including: a) participant characteristics (presentation, prior testing), b) clinical setting, c) study design, d) target condition definition, e) index test, f) reference standard, g) sample size, h) funding sources	Page6-7/Line154-164	RESULTS/Para2
Risk of bias and applicability	19	Present evaluation of risk of bias and concerns regarding applicability for each study.	Page7/Line166-171	RESULTS/Para3
Results of individual studies	20	For each analysis in each study (e.g. unique combination of index test, reference standard, and positivity threshold) report 2x2 data (TP, FP, FN, TN) with estimates of diagnostic accuracy and confidence intervals, ideally with a forest or receiver operator characteristic (ROC) plot.	Page7-8/Line173-205	RESULTS/Para4-6
Synthesis of results	21	Describe test accuracy, including variability; if meta-analysis was done, include results and confidence intervals.	Page7/Line174-183	RESULTS/Para4
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression; analysis of index test: failure rates, proportion of inconclusive results, adverse events).	Page7-8/Line185-205	RESULTS/Para5-6
DISCUSSION				
Summary of evidence	24	Summarize the main findings including the strength of evidence.	Page10/Line266-271	DISCUSSION/Para4
Limitations	25	Discuss limitations from included studies (e.g. risk of bias and concerns regarding applicability) and from the review process (e.g. incomplete retrieval of identified research).	Page10-11/Line272-281	DISCUSSION/Para5

Conclusions	26	Provide a general interpretation of the results in the context of other evidence. Discuss implications for future research and clinical practice (e.g. the intended use and clinical role of the index test).	Page11/Line283-294	Conclusion/Para1-2
FUNDING				
Funding	27	For the systematic review, describe the sources of funding and other support and the role of the funders.	Page11/Line299-300	Funding

Adapted From: McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, The PRISMA-DTA Group (2018). Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018 Jan 23;319(4):388-396. doi: 10.1001/jama.2017.19163.

Table 2 PRISMA-DTA for Abstracts Checklist

Section/topic	#	PRISMA-DTA Checklist Item	Reported on Page Number/Line Number	Reported on Section/Paragraph
TITLE and PURPOSE				
Title	1	Identify the report as a systematic review (+/- meta-analysis) of diagnostic test accuracy (DTA) studies.	Page1/Line1-3	Title
Objectives	2	Indicate the research question, including components such as participants, index test, and target conditions.	Page2/Line33-37	Abstracts/Para1
METHODS				
Eligibility criteria	3	Include study characteristics used as criteria for eligibility.	Page2/Line38-43	Abstracts/Para2
Information sources	4	List the key databases searched and the search dates.	Page2/Line38-43	Abstracts/Para2
Risk of bias & applicability	5	Indicate the methods of assessing risk of bias and applicability.	Page2/Line38-43	Abstracts/Para2
Synthesis of results	A1	Indicate the methods for the data synthesis.	Page2/Line38-43	Abstracts/Para2
RESULTS				
Included studies	6	Indicate the number and type of included studies and the participants and relevant characteristics of the studies (including the reference standard).	Page2/Line44-51	Abstracts/Para3
Synthesis of results	7	Include the results for the analysis of diagnostic accuracy, preferably indicating the number of studies and participants. Describe test accuracy including variability; if meta-analysis was done, include summary results and confidence intervals.	Page2/Line44-51	Abstracts/Para3

DISCUSSION				
Strengths and limitations	9	Provide a brief summary of the strengths and limitations of the evidence	Page2/Line52-60	Abstracts/Para4
Interpretation	10	Provide a general interpretation of the results and the important implications.	Page2/Line52-60	Abstracts/Para4
OTHER				
Funding	11	Indicate the primary source of funding for the review.	Page11/Line299-300	Funding
Registration	12	Provide the registration number and the registry name	Page5/Line104	Method/Para1

Adapted From: McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, The PRISMA-DTA Group (2018). Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018 Jan 23;319(4):388-396. doi: 10.1001/jama.2017.19163.

Article information: https://dx.doi.org/10.21037/atm-22-6587
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.